IRCT201211124365N15已完成2 期
Determination of optimal prophylactic dose of magnesium sulfate for prevention of atrial fibrillation after CABG surgery
Vice chancellor for research of Mazandaran University of Medical Sciences0 个研究点目标入组 120 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 35 years 至 75 years（—）
- 性别
- All
入选标准
- •signing informed consent; candidate for elective CABG based on angiography; use of cardiopulmonary bypass (CBP) during surgery; no previous history of any cardiac dysrhythmias that is under treatment ( including AF); hemodynamic stability ( MAP>50, heart rate between 50-110); age between 35&75 years old.
- •Exclusion criteria: history of heart failure (Ejection Fraction less than 30%); more than 4 grafts; renal failure ( serum creatinine >1.5 in two consecutive test); hepatic failure ( liver function tests more than 1.5 times of normal value); history of COPD; hyperthyroidism; serum PH < 7.25 or > 7.55; postoperative MI; second or third degree AV block; need for pacemaker after surgery; reoperation for any reason; history of pervious cardiac surgery; anti-arrhythmic drugs consumption (except beta blocker).
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
Evaluation of the optimal dose of prophylactic anticoagulation with low- molecular- weight heparin administered subcutaneously to critically ill patients – part 2 - LMWH prophylaxis for ICU patientsMedDRA version: 12.1Level: LLTClassification code 10049909Term: Venous thromboembolism prophylaxisvenous thromboembolismEUCTR2010-022034-88-DKOdense University Hospital
进行中（未招募）
1 期
Evaluation of the optimal dose of prophylactic anticoagulation with low-molecular-weight heparine administered subcutaneously to critically ill patients - low-molecular-weight heparin in critically ill patientsEUCTR2005-002381-10-DKDept anaesthesiology and intensive care80
进行中（未招募）
不适用
Determination of the efficacious and safe dose of ivabradine in paediatric patients with dilated cardiomyopathy and symptomatic chronic heart failure aged from 6 months to less than 18 yearsEUCTR2011-001292-39-HUInstitut de Recherches Internationales Servier90
进行中（未招募）
不适用
Determination of the efficacious and safe dose of ivabradine in paediatric patients with dilated cardiomyopathy and symptomatic chronic heart failure aged from 6 months to less than 18 yearsPaediatric dilated cardiomyopathy and symptomatic chronic heart failureMedDRA version: 14.1Level: LLTClassification code 10008908Term: Chronic heart failureSystem Organ Class: 10007541 - Cardiac disordersEUCTR2011-001292-39-SEInstitut de Recherches Internationales Servier90
进行中（未招募）
1 期
Determination of the efficacious and safe dose of ivabradine in paediatric patients with dilated cardiomyopathy and symptomatic chronic heart failure aged from 6 months to less than 18 yearsPaediatric dilated cardiomyopathy and symptomatic chronic heart failureMedDRA version: 14.1Level: LLTClassification code 10008908Term: Chronic heart failureSystem Organ Class: 10007541 - Cardiac disordersEUCTR2011-001292-39-ESab Servier116